GEN Exclusives

More »

GEN News Highlights

More »
Oct 30, 2007

Sapphire Licenses a Novo Nordisk Program Related to Obesity Therapeutics

  • Sapphire Therapeutics licensed a discovery-stage ghrelin antagonist program from Novo Nordisk. These candidates are being researched and developed as potential obesity treatments.

    “Ghrelin, as the only known systemically acting appetite-stimulating hormone, offers a new and very specific target for antagonist drug intervention,” explains William J. Polvino, M.D., Sapphire's president and CEO.

    Sapphire focuses on developing drugs that act on the ghrelin receptor against metabolic and oncologic diseases. “Licensing this promising discovery-stage ghrelin antagonist program from Novo Nordisk complements Sapphire's clinical-stage agonist program and increases the breadth of our ghrelin portfolio,” Dr. Polvino adds. Thus far, the company has a Phase II candidate being tested in cancer patients with anorexia/cachexia syndrome and ipamorelin and  a compound in Phase I/II studies in postoperative ileus.



Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Should “Special K” Get Special Treatment?

In the near term, what is the best way to use ketamine in treating depression?